Friday, May 1, 2020

Dr. Fauci on remdesivir for COVID-19: ‘This will be the standard of care’

National Institute of Allergy and Infectious Diseases Director Anthony S. Fauci, MD, said today that data from a multinational randomized control trial showed that Gilead’s investigational antiviral remdesivir “has a clear-cut significant positive effect in diminishing time to recovery” for patients with COVID-19.
“This will be the standard of care,” Fauci, a White House advisor on the pandemic, said during comments from the Oval Office. Fauci said the results, which have not yet been peer-reviewed, prove “that a drug can block this virus.”
Read more:

Gilead Sciences, Inc. /ˈɡɪliəd/, is an American biopharmaceutical company that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIVhepatitis Bhepatitis C, and influenza, including Harvoni and Sovaldi.

No comments:

Post a Comment